Skip to main content
. Author manuscript; available in PMC: 2021 Mar 4.
Published in final edited form as: Trends Cancer. 2020 Feb 5;6(2):98–110. doi: 10.1016/j.trecan.2020.01.007

Figure 1. Breast Cancer Patient Survival after Stratification for TP53 Status and Treatment.

Figure 1.

Median survival was determined for patients from the METABRIC database, stratified by TP53 mutation status and treatment exposure. Studies that analyzed patients under similar treatment conditions are listed in adjacent captions. (A) All patients (P <0.0001). (B) All chemotherapy-treated patients (P = ns). (C) All patients who did not receive chemotherapy (P <0.0001). (D) All patients treated with chemotherapy + HRT (P <0.05). (E) All patients treated with chemotherapy alone (P <0.05). (F) All patients treated with HRT only (P <0.0001). (G) All patients who did not receive chemotherapy or HRT (P = ns). Abbreviations: HRT, hormonal therapies; mut, mutant; ns, not significant; OS, overall survival; WT, wild type. (See [9,39–49,52–54,65–91].)